Biomarkers for cardiovascular risk in children

Current Opinion in Cardiology

Volumn 28, Issue 2, 2013, Pages 103-114

  Canas, Jose A ^a,b   Sweeten, Shawn ^a   Balagopal, Prabhakaran ^a,b  

^a NEMOURS CHILDREN S CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

biomarkers; cardiovascular disease; inflammation; obesity; pediatrics

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; D DIMER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; HOMOCYSTEINE; HORMONE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 8; ISOPROSTANE DERIVATIVE; LEUKOTRIENE; LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE; OBESTATIN; PADGEM PROTEIN; SERUM AMYLOID A; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1; VITAMIN; VON WILLEBRAND FACTOR;

ABDOMINAL AORTA; ADIPOSE TISSUE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILDHOOD DISEASE; CHILDHOOD OBESITY; DIETARY INTAKE; DISEASE COURSE; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; ERYTHROCYTE SEDIMENTATION RATE; FIBRINOLYSIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LEUKOCYTE; MACROPHAGE; MONOCYTE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RIGHT CORONARY ARTERY; SATIETY;

ADIPOKINES; BIOLOGICAL MARKERS; BLOOD COAGULATION DISORDERS; CARDIOVASCULAR DISEASES; CHILD; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN RESISTANCE; LIFE STYLE; OXIDATIVE STRESS; PROGNOSIS; RISK FACTORS;

EID: 84873432197     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32835dd0ce     Document Type: Review

References (162)

1. Berenson GS, Srnivasan SR. Cardiovascular risk factors in youth with implications for aging: The Bogalusa Heart Study. Neurobiol Aging 2005; 26:303-307.
2. Daniels SR, Pratt CA, Hayman LL. Reduction of risk for cardiovascular disease in children and adolescents. Circulation 2011; 124:1673-1686.
3. Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease: Six year follow-up experience. The Framingham Study. Ann Intern Med 1961; 55:33-50.
4. Dawber TR, Kannel WB. The Framingham Study. An epidemiological approach to coronary heart disease. Circulation 1966; 34:553-555.
5. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113:2335-2362.
6. Ge Y, Wang TJ. Circulating, imaging, and genetic biomarkers in cardiovascular risk prediction. Trends Cardiovasc Med 2011; 21:105-112.
7. Balagopal P, de Ferranti SD, Cook S, et al. Nontraditional risk factors and biomarkers for cardiovascular disease: mechanistic, research, and clinical considerations for youth Y a scientific statement from the American Heart Association. Circulation 2011; 123:2749-2769.
8. Ridker PM, Brown NJ, Vaughan DE, et al. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109:IV6-IV19.
9. Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: A scientific statement from the American Heart Association. Circulation 2009; 119:2408-2416.
10. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011; 123:551-565.
11. Dadu RT, Nambi V, Ballantyne CM. Developing and assessing cardiovascular biomarkers. Transl Res 2012; 159:265-276.
12. Balagopal P. Obesity-related cardiovascular risk in children and the role of lifestyle changes. J Cardiometab Syndr 2006; 1:267-274.
13. Steinberger J, Daniels SR, Eckel RH, et al. Progress and challenges in metabolic syndrome in children and adolescents: A scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2009; 119:628-647.
14. Montero D, Walther G, Perez-Martin A, et al. Endothelial dysfunction, inflammation, and oxidative stress in obese children and adolescents: markers and effect of lifestyle intervention. Obes Rev 2012; 13:441-455.
15. Buchan DS, Thomas NE, Baker JS. Novel risk factors of cardiovascular disease and their associations between obesity, physical activity and physical fitness. J Public Health Res 2012; 1:59-66.
16. Tam CS, Clement K, Baur LA, Tordjman J. Obesity and low-grade inflammation: A paediatric perspective. Obes Rev 2010; 11:118-126.
17. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012; 307:483-490.
18. Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med 2011; 365:1876-1885.
19. Weintraub WS, Daniels SR, Burke LE, et al. Value of primordial and primary prevention for cardiovascular disease. Circulation 2011; 124: 967-990.
20. McGill HC, McMahan CA, Malcom GT, et al., for the PDAY Research Group. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. Arterioscler Thromb Vasc Biol 1997; 17:95-106.
21. McGill HC Jr,McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. Arterioscler Thromb Vasc Biol 2000; 20:1998-2004.
22. Newman WP, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. N Engl J Med 1986; 314:138-144.
23. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998; 338: 1650-1656.
24. Juonala M, Magnussen CG, Venn A, et al. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood/clinical perspective. Circulation 2010; 122:2514-2520.
25. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32:2045-2051.
26. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111:3481-3488.
27. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860-867.
28. Visser M, Bouter LM, McQuillan GM, et al. Low-grade systemic inflammation in overweight children. Pediatrics 2001; 107:E13.
29. Ford ES, Giles WH, Myers GL, et al. C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. Clin Chem 2003; 49:1353-1357.
30. Zieske AW, Tracy RP, McMahan CA, et al. Elevated serum C-reactive protein levels and advanced atherosclerosis in youth. Arterioscler Thromb Vasc Biol 2005; 25:1237-1243.
31. Dowd JB, Zajacova A, Aiello AE. Predictors of inflammation in U.S. children aged 3-16 years. Am J Prev Med 2010; 39:314-320.
32. Balagopal P, George D, Patton N, et al. Lifestyle-only intervention attenuates the inflammatory state associated with obesity: A randomized controlled study in adolescents. J Pediatr 2005; 146:342-348.
33. Norris AL, Steinberger J, Steffen LM, et al. Circulating oxidized LDL and inflammation in extreme pediatric obesity. Obesity 2011; 19:1415-1419.
34. Kelly AS, Wetzsteon RJ, Kaiser DR, et al. Inflammation, insulin, and endothelial function in overweight children and adolescents: The role of exercise. J Pediatr 2004; 145:731-736.
35. Juonala M, Viikari JSA, Ronnemaa T, et al. Childhood C-reactive protein in predicting CRP and carotid intima-media thickness in adulthood: The cardiovascular risk in young Finns study. Arterioscler Thromb Vasc Biol 2006; 26:1883-1888.
36. Moran A, Steffen LM, Jacobs DR Jr, et al. Relation of C-reactive protein to insulin resistance and cardiovascular risk factors in youth. Diabetes Care 2005; 28:1763-1768.
37. Ford ES, Ajani UA, Mokdad AH. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care 2005; 28:878-881.
38. Vikram NK, Misra A, Pandey RM, et al. Adiponectin, insulin resistance, and Creactive protein in postpubertal Asian Indian adolescents. Metabolism 2004; 53:1336-1341.
39. de Ferranti SD, Gauvreau K, Ludwig DS, et al. Inflammation and changes in metabolic syndrome abnormalities in US adolescents: findings from the 1988-1994 and 1999-2000 National Health and Nutrition Examination Surveys. Clin Chem 2006; 52:1325-1330.
40. Kelishadi R, Hashemi M, Mohammadifard N, et al. Association of changes in oxidative and proinflammatory states with changes in vascular function after a lifestyle modification trial among obese children. Clin Chem 2008; 54:147-153.
41. Parrett AL, Valentine RJ, Arngrimsson SA, et al. Adiposity, activity, fitness, and C-reactive protein in children. Med Sci Sports Exerc 2010; 42:1981-1986.
42. Jarvisalo MJ, Harmoinen A, Hakanen M, et al. Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler Thromb Vasc Biol 2002; 22:1323-1328.
43. Gallistl S, Sudi KM, Aigner R, Borkenstein M. Changes in serum interleukin-6 concentrations in obese children and adolescents during a weight reduction program. Int J Obes 2001; 25:1640-1643.
44. Okita K, Nishijima H, Murakami T, et al. Can exercise training with weight loss lower serum C-reactive protein levels? Arterioscler Thromb Vasc Biol 2004; 24:1868-1873.
45. Reinehr T, Stoffel-Wagner B, Roth CL, Andler W. High-sensitive C-reactive protein, tumor necrosis factor alpha, and cardiovascular risk factors before and after weight loss in obese children. Metabolism 2005; 54:1155-1161.
46. Meyer AA, Kundt G, Lenschow U, et al. Improvement of early vascular changes and cardiovascular risk factors in obese children after a six-month exercise program. J Am Coll Cardiol 2006; 48:1865-1870.
47. Park TG, Hong HR, Lee J, Kang HS. Lifestyle plus exercise intervention improves metabolic syndrome markers without change in adiponectin in obese girls. Ann Nutr Metab 2007; 51:197-203.
48. Roth CL, Kratz M, Ralston MM, Reinehr T. Changes in adipose-derived inflammatory cytokines and chemokines after successful lifestyle intervention in obese children. Metabolism 2011; 60:445-452.
49. Mauras N, DelGiorno C, Hossain J, et al. Metformin use in children with obesity and normal glucose tolerance: Effects on cardiovascular markers and intrahepatic fat. J Pediatr Endocrinol Metab 2012; 25: 33-40.
50. Kamal NN, Ragy MM. The effects of exercise on C-reactive protein, insulin, leptin and some cardiometabolic risk factors in Egyptian children with or without metabolic syndrome. Diabet Metab Syndr 2012; 4:27.
51. Nassis GP, Papantakou K, Skenderi K, et al. Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin, and inflammatory markers in overweight and obese girls. Metabolism 2005; 54:1472-1479.
52. Ferguson MA, Gutin B, Owens S, et al. Effects of physical training and its cessation on the hemostatic system of obese children. Am J Clin Nutr 1999; 69:1130-1134.
53. Barbeau P, Litaker M, Woods KF, et al. Hemostatic and inflammatory markers in obese youths: Effects of exercise and adiposity. J Pediatr 2002; 141:415-420.
54. Kelly AS, Steinberger J, Olson TP, Dengel DR. In the absence of weight loss, exercise training does not improve adipokines or oxidative stress in overweight children. Metabolism 2007; 56:1005-1009.
55. Farpour-Lambert NJ, Aggoun Y, Marchand LM, et al. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J Am Coll Cardiol 2009; 54:2396-2406.
56. Satchell M, Mann K, Balagopal PB. Do obese children have chronic inflammation & could this contribute to future CVD risk? Curr Cardiovasc Risk Rep 2012; 6:579-590.
57. Urbina EM, Williams RV, Alpert BS, et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: Recommendations for standard assessment for clinical research Y a scientific statement from the American Heart Association. Hypertension 2009; 54:919-950.
58. Duda DG, Cohen KS, Scadden DT, Jain RK. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protocols 2007; 2:805-810.
59. Kelly AS, Hebbel RP, Solovey AN, et al. Circulating activated endothelial cells in pediatric obesity. J Pediatr 2010; 157:547-551.
60. Arnold C, Wenta D, Muller-Ehmsen J, et al. Progenitor cell number is correlated to physical performance in obese children and young adolescents. Cardiol Young 2010; 20:381-386.
61. Walther C, Gaede L, Adams V, et al. Effect of increased exercise in school children on physical fitness and endothelial progenitor cells. Circulation 2009; 120:2251-2259.
62. Park JH, Miyashita M, Kwon YC, et al. A 12-week after-school physical activity programme improves endothelial cell function in overweight and obese children: A randomised controlled study. BMC Pediatr 2012; 12:111.
63. Dorman JS, Laporte RE, Kuller LH, et al. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results. Diabetes 1984; 33:271-276.
64. Caballero AE, Bousquet-Santos K, Robles-Osorio L, et al. Overweight Latino children and adolescents have marked endothelial dysfunction and subclinical vascular inflammation in association with excess body fat and insulin resistance. Diabetes Care 2008; 31:576-582.
65. Maggio ABR, Wacker J, Montecucco F, et al. Serum resistin and inflammatory and endothelial activation markers in obese adolescents. J Pediatr 2012; 161:1022-1027.
66. Bhattacharjee R, Alotaibi W, Kheirandish-Gozal L, et al. Endothelial dysfunction in obese nonhypertensive children without evidence of sleep disordered breathing. BMC Pediatr 2010; 10:8.
67. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170:191-203.
68. Ponthieux A, Herbeth B, Droesch S, et al. Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: The Stanislas study. Atherosclerosis 2004; 172:299-308.
69. Kaye SM, Pietilainen KH, Kotronen A, et al. Obesity-related derangements of coagulation and fibrinolysis: A study of obesity-discordant monozygotic twin pairs. Obesity 2012; 20:88-94.
70. Raiko JRH, Oikonen M, Wendelin-Saarenhovi M, et al. Plasminogen activator inhibitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study. Atherosclerosis 2012; 224:208-212.
71. Fibrinogen Studies Collaboration. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: Individual participant meta-analysis of 154 211 adults in 31 prospective studies. Am J Epidemiol 2007; 166:867-879.
72. Bao W, Srinivasan SR, Berenson G. Plasma fibrinogen and its correlates in children from a biracial community: The Bogalusa Heart Study. Pediatr Res 1993; 33:323-326.
73. Ferguson MA, Gutin B, Owens S, et al. Fat distribution and hemostatic measures in obese children. Am J Clin Nutr 1998; 67:1136-1140.
74. Gallistl S, Sudi KM, Borkenstein M, et al. Determinants of haemostatic risk factors for coronary heart disease in obese children and adolescents. Int J Obes 2000; 24:1459-1464.
75. Balagopal P, Sweeten S, Mauras N. Increased synthesis rate of fibrinogen as a basis for its elevated plasma levels in obese female adolescents. Am J Physiol 2002; 282:E899-E904.
76. Balagopal P, George D, Sweeten S, et al. Response of fractional synthesis rate (FSR) of fibrinogen, D-dimer and fibrinolytic balance to physical activitybased intervention in obese children. J Thromb Haemost 2008; 6:1296-1303.
77. Giordano P, Del Vecchio G, Cecinati V, et al. Metabolic, inflammatory, endothelial and haemostatic markers in a group of Italian obese children and adolescents. Eur J Pediatr 2011; 170:845-850.
78. Green D, Chan C, Kang J, et al. Longitudinal assessment of fibrinogen in relation to subclinical cardiovascular disease: The CARDIA study. J Thromb Haemost 2010; 8:489-495.
79. Fritsch P, Kleber M, Rosenkranz A, et al. Haemostatic alterations in overweight children: Associations between metabolic syndrome, thrombin generation, and fibrinogen levels. Atherosclerosis 2010; 212: 650-655.
80. Mauras N, DelGiorno C, Kollman C, et al. Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children. J Clin Endocrinol Metab 2010; 95:1060-1068.
81. Stoppa-Vaucher S, Dirlewanger MA, Meier CA, et al. Inflammatory and prothrombotic states in obese children of European descent. Obesity 2012; 20:1662-1668.
82. Bilge YD, Alioglu B, Simdek E, et al. Increased coagulation in childhood obesity. Pediatr Hematol Oncol 2012; 29:721-727.
83. Lord ST. Fibrinogen and fibrin: Scaffold proteins in hemostasis. Curr Opin Hematol 2007; 14:236-241.
84. Lovely RS, Kazmierczak SC, Massaro JM, et al. g' Fibrinogen: Evaluation of a new assay for study of associations with cardiovascular disease. Clin Chem 2010; 56:781-788.
85. Alexander KS, Madden TE, Farrell DH. Association between g' fibrinogen levels and inflammation. Thromb Haemost 2011; 105:605-609.
86. Falls LA, Farrell DH. Resistance of g/g' fibrin clots to fibrinolysis. J Biol Chem 1997; 272:14251-14256.
87. Uitte de Willige S, Standeven KF, Philippou H, Ariens RAS. The pleiotropic role of the fibrinogen g' chain in hemostasis. Blood 2009; 114:3994-4001.
88. Lovely RS, Yang Q, Massaro JM, et al. Assessment of genetic determinants of the association of g'-fibrinogen in relation to cardiovascular disease. Arterioscler Thromb Vasc Biol 2011; 31:2345-2352.
89. Lovely RS, Ramsey JP, Hossain J, et al. Physical activity-induced reduction in elevated gamma' (g') fibrinogen in obese children: A randomized controlled study [abstract]. Obesity 2012; 558:S178.
90. Jimenez MV, Estepa RM, Camacho RM, et al. Endothelial dysfunction is related to insulin resistance and inflammatory biomarker levels in obese prepubertal children. Eur J Endocrinol 2007; 156:497-502.
91. Semeraro F, Giordano P, Faienza MF, et al. Evidence that fibrinolytic changes in paediatric obesity translate into a hypofibrinolytic state. Relative contribution of TAFI and PAI-1. Thromb Haemost 2012; 108:311-317.
92. Singh A, Foster GD, Gunawardana J, et al. Elevated circulating tissue factor procoagulant activity, factor VII, and plasminogen activator inhibitor-1 in childhood obesity: Evidence of a procoagulant state. Br J Haematol 2012; 158:523-527.
93. Huang F, Rio-Navarro BE, de Castro GTM, et al. Weight loss induced by 6-month lifestyle intervention improves early endothelial activation and fibrinolysis in obese adolescents. Child Care Health Dev 2011; 37:377-384.
94. Izadpanah A, Barnard RJ, Almeda AJ, et al. A short-term diet and exercise intervention ameliorates inflammation and markers of metabolic health in overweight/obese children. Am J Physiol Endocrinol Metab 2012; 303: E542-E550.
95. Gallistl S, Sudi KM, Cvirn G, et al. Effects of short-term energy restriction and physical training on haemostatic risk factors for coronary heart disease in obese children and adolescents. Int J Obes 2001; 25:529-532.
96. Vind J, Gleerup G, Nielsen PT, Winther K. The impact of static work on fibrinolysis and platelet function. Thromb Res 1993; 72:441-446.
97. El-Sayed MS. Effects of exercise on blood coagulation, fibrinolysis and platelet aggregation. Sports Med 1996; 22:282-298.
98. Sudi KM, Gallistl S, Trobinger M, et al. The influence of weight loss on fibrinolytic and metabolic parameters in obese children and adolescents. J Pediatr Endocrinol Metab 2001; 14:85-94.
99. Liu J, Young TK, Zinman B, et al. Lifestyle variables, nontraditional cardiovascular risk factors, and the metabolic syndrome in an Aboriginal Canadian population. Obesity 2006; 14:500-508.
100. Reinehr T, Roth C, Menke T, Andler W. Adiponectin before and after weight loss in obese children. J Clin Endocrinol Metab 2004; 89:3790-3794.
101. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350:2362-2374.
102. Balagopal P, George D, Yarandi H, et al. Reversal of obesity-related hypoadiponectinemia by lifestyle intervention: A controlled, randomized study in obese adolescents. J Clin Endocrinol Metab 2005; 90:6192-6197.
103. Araki S, Dobashi K, Kubo K, et al. High molecular weight, rather than total, adiponectin levels better reflect metabolic abnormalities associated with childhood obesity. J Clin Endocrinol Metab 2006; 91:5113-5116.
104. Martos-Moreno GA, Barrios V, Martinez G, et al. Effect of weight loss on highmolecular weight adiponectin in obese children. Obesity 2010; 18:2288-2294.
105. Ochiai H, Shirasawa T, Nishimura R, et al. High-molecular-weight adiponectin and anthropometric variables among elementary schoolchildren: A population-based cross-sectional study in Japan. BMC Pediatrics 2012; 12:139.
106. Murdolo G, Nowotny B, Celi F, et al. Inflammatory adipokines, high molecular weight adiponectin, and insulin resistance: A population-based survey in prepubertal schoolchildren. PLoS ONE 2011; 6:e17264.
107. Masquio DC, de Piano A, Sanches PL, et al. The effect of weight loss magnitude on pro/anti-inflammatory adipokines and carotid intima-media thickness in obese adolescents engaged in interdisciplinary weight-loss therapy. Clin Endocrinol (Oxf) 2012. doi: 10.1111/j.1365-2265.2012.
108. Balagopal P, Gidding SS, Buckloh LM, et al. Changes in circulating satiety hormones in obese children: A randomized controlled physical activity-based intervention study. Obesity 2010; 18:1747-1753.
109. Spruijt-Metz D, Adar Emken B, Spruijt MR, et al. CRP is related to higher leptin levels in minority peripubertal females regardless of adiposity levels. Obesity 2012; 20:512-516.
110. Ikejima K, Honda H, Yoshikawa M, et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001; 34:288-297.
111. Stelzer I, Zelzer S, Raggam RB, et al. Link between leptin and interleukin-6 levels in the initial phase of obesity related inflammation. Transl Res 2012; 159:118-124.
112. Balagopal P, Graham TE, Kahn BB, et al. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: Association with subclinical inflammation. J Clin Endocrinol Metab 2007; 92:1971-1974.
113. Lee DC, Lee JW, Im JA. Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents. Metabolism 2007; 56:327-331.
114. Aeberli I, Biebinger R, Lehmann R, et al. Serum retinol-binding protein 4 concentration and its ratio to serum retinol are associated with obesity and metabolic syndrome components in children. J Clin Endocrinol Metab 2007; 92:4359-4365.
115. Goodman E, Graham TE, Dolan LM, et al. The relationship of retinol binding protein 4 to changes in insulin resistance and cardiometabolic risk in overweight black adolescents. J Pediatr 2009; 154:67-73.
116. Reinehr T, Stoffel-Wagner B, Roth CL. Adipocyte fatty acid binding protein in obese children before and after weight loss. Metabolism 2007; 56:1735-1741.
117. Aeberli I, Beljean N, Lehmann R, et al. The increase of fatty acid-binding protein aP2 in overweight and obese children: Interactions with dietary fat and impact on measures of subclinical inflammation. Int J Obes 2008; 32:1513-1520.
118. Choi KM, Yannakoulia M, Park MS, et al. Serum adipocyte fatty acid binding protein, retinol-binding protein 4, and adiponectin concentrations in relation to the development of the metabolic syndrome in Korean boys: A 3-y prospective cohort study. Am J Clin Nutr 2011; 93:19-26.
119. Bhushan B, Khalyfa A, Spruyt K, et al. Fatty-acid binding protein 4 gene polymorphisms and plasma levels in children with obstructive sleep apnea. Sleep Med 2011; 12:666-671.
120. Bronsky J, Mitrova K, Karpisek M, et al. Adiponectin, AFABP, and leptin in human breast milk during 12 months of lactation. J Pediatr Gastroenterol Nutr 2011; 52:474-477.
121. Xu A, Vanhoutte PM. Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol 2012; 302:H1231-H1240.
122. Sinaiko AR, Steinberger J, Moran A, et al. Relation of body mass index and insulin resistance to cardiovascular risk factors, inflammatory factors, and oxidative stress during adolescence. Circulation 2005; 111:1985-1991.
123. Turi S, Friedman A, Bereczki C, et al. Oxidative stress in juvenile essential hypertension. J Hypertens 2003; 21:145-152.
124. Kelly AS, Steinberger J, Kaiser DR, et al. Oxidative stress and adverse adipokine profile characterize the metabolic syndrome in children. J Cardiometab Syndr 2006; 1:248-252.
125. Loffredo L, Martino F, Carnevale R, et al. Obesity and hypercholesterolemia are associated with NOX2 generated oxidative stress and arterial dysfunction. J Pediatr 2012; 161:1004-1009.
126. Karamouzis I, Pervanidou P, Berardelli R, et al. Enhanced oxidative stress and platelet activation combined with reduced antioxidant capacity in obese prepubertal and adolescent girls with full or partial metabolic syndrome. Horm Metab Res 2011; 43:607-613.
127. Chiavaroli V, Giannini C, D'Adamo E, et al. Insulin resistance and oxidative stress in children born small and large for gestational age. Pediatrics 2009; 124:695-702.
128. Araki S, Dobashi K, Yamamoto Y, et al. Increased plasma isoprostane is associated with visceral fat, high molecular weight adiponectin, and metabolic complications in obese children. Eur J Pediatr 2010; 169:965-970.
129. Oliver SR, Rosa JS, Milne GL, et al. Increased oxidative stress and altered substrate metabolism in obese children. Int J Pediatr Obes 2010; 5:436-444.
130. de Ferranti SD, Daniels SR, Gillman M, et al. NHLBI Integrated Guidelines on Cardiovascular Disease Risk Reduction. Clin Chem 2012; 58:1626-1630.
131. Cook S, Kavey RE. Dyslipidemia and pediatric obesity. Pediatr Clin North Am 2011; 58:1363-1373.
132. Gidding SS, Daniels SR, Kavey RE, for the Expert Panel on Cardiovascular Health and Risk Reduction in Youth Developing the 2011 Integrated Pediatric Guidelines for Cardiovascular Risk Reduction. Pediatrics 2012; 129:e1311-e1319.
133. Kit BK, Carol MD, Lacher DA, et al. Trends in serum lipids among US youths aged 6 to 19 years, 1988-2010. JAMA 2012; 308:591-600.
134. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307:491-497.
135. Walldius G, Jungner I. The apoB/apoA-I ratio: A strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy Y a review of the evidence. J Intern Med 2006; 259:493-519.
136. Juonala M, Viikari JSA, Kahonen M, et al. Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: The Cardiovascular Risk in Young Finns study. J Am Coll Cardiol 2008; 52:293-299.
137. Benson M, Hossain J, Caulfield MP, et al. Lipoprotein subfractions by ion mobility in lean and obese children. J Pediatr 2012; 161:997-1003.
138. Sellers EAC, Singh GR, Sayers SM. Apo-B/AI ratio identifies cardiovascular risk in childhood: The Australian Aboriginal Birth Cohort study. Diabet Vasc Dis Res 2009; 6:94-99.
139. Ben Ounis O, Elloumi M, Makni E, et al. Exercise improves the ApoB/ApoA-I ratio, a marker of the metabolic syndrome in obese children. Acta Pediatr 2010; 99:1679-1685.
140. Frontini MG, Srinivasan SR, Xu J, et al. Usefulness of childhood non-high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: The Bogalusa Heart Study. Pediatrics 2008; 121:924-929.
141. Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: The Bogalusa Heart Study. JAMA 2003; 290:2271-2276.
142. Zelzer S, Fuchs N, Almer G, et al. High density lipoprotein cholesterol level is a robust predictor of lipid peroxidation irrespective of gender, age, obesity, and inflammatory or metabolic biomarkers. Clin Chim Acta 2011; 412:1345-1349.
143. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364:127-135.
144. Garza CA,Montori VM, McConnell JP, et al. Association between lipoproteinassociated phospholipase A2 and cardiovascular disease: A systematic review. Mayo Clin Proc 2007; 82:159-165.
145. Ridker PM, MacFadyen JG, Wolfert RL, Koenig W. Relationship of lipoprotein-associated phospholipase A2 mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: An analysis from the JUPITER trial. Clin Chem 2012; 58:877-886.
146. Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA 2012; 307:2499-2506.
147. Barker DJP, Eriksson JG, Forsen T, Osmond C. Fetal origins of adult disease: Strength of effects and biological basis. Int J Epidemiol 2002; 31:1235-1239.
148. Gregor MF, Hotamisligil GKS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29:415-445.
149. Nadeau KJ, Maahs DM, Daniels SR, Eckel RH. Childhood obesity and cardiovascular disease: links and prevention strategies. Nat Rev Cardiol 2011; 8:513-525.
150. Daniels SR, Jacobson MS, McCrindle BW, et al. American Heart Association Childhood Obesity Research Summit: Executive summary. Circulation 2009; 119:2114-2123.
151. Riccioni G, Speranza L, Pesce M, et al. Novel phytonutrient contributors to antioxidant protection against cardiovascular disease. Nutrition 2012; 28:605-610.
152. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010; 152:315-323.
153. Codoner-Franch P, Valls-Belles V, Arilla-Codoner A, Alonso-Iglesias E. Oxidant mechanisms in childhood obesity: The link between inflammation and oxidative stress. Transl Res 2011; 158:369-384.
154. Myhrstad M, Retterstol K, Telle-Hansen V, et al. Effect of marine n-3 fatty acids on circulating inflammatory markers in healthy subjects and subjects with cardiovascular risk factors. Inflamm Res 2011; 60:309-319.
155. Gibson RA, Muhlhausler B, Makrides M. Conversion of linoleic acid and alpha-linolenic acid to long-chain polyunsaturated fatty acids (LCPUFAs), with a focus on pregnancy, lactation and the first 2 years of life. Matern Child Nutr 2011; 7:17-26.
156. Johnson MD, Nader NS, Weaver AL, et al. Relationships between 25-hydroxyvitamin D levels and plasma glucose and lipid levels in pediatric outpatients. J Pediatr 2010; 156:444-449.
157. Williams DM, Fraser A, Sayers A, et al. Associations of 25-hydroxyvitamin D2 and D3 with cardiovascular risk factors in childhood: cross-sectional findings from the Avon longitudinal study of parents and children. J Clin Endocrinol Metab 2012; 97:1563-1571.
158. Rajakumar K, las Heras J, Chen TC, et al. Vitamin D status, adiposity, and lipids in black American and Caucasian children. J Clin Endocrinol Metab 2011; 96:1560-1567.
159. Ford ES, Gillespie C, Ballew C, et al. Serum carotenoid concentrations in US children and adolescents. Am J Clin Nutr 2002; 76:818-827.
160. Beydoun MA, Canas JA, Beydoun HA, et al. Serum antioxidant concentrations and metabolic syndrome are associated among U.S. adolescents in recent National Surveys. J Nutr 2012; 142:1693-1704.
161. Canas JA, Damaso L, Altomare A, et al. Insulin resistance and adiposity in relation to serum b-carotene levels. J Pediatr 2012; 161: 58-64.
162. Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant concentrations. Diabetes 2003; 52:2346-2352.